Isolation and characterization of an anti-recombinant erythropoietin single-chain antibody fragment using a phage display antibody library

Mi, Jiebo; Jin, Yan; Guo, Zhiqiang; Zhao, Meiping; Chang, Wen‐Bao

doi:10.1007/s00216-005-3401-3

Cited by 7 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also the SRP pathway can be used for antibody fragment production (55). After expression, recombinant antibodies are usually isolated from the periplasmic fraction (56, 57) but also from the culture supernatant (58–61). …”

Section: Antibody Production In Prokaryotic Hostsmentioning

confidence: 99%

Expression of Recombinant Antibodies

Frenzel¹,

Hust²,

Schirrmann³

2013

Front. Immunol.

279

220

View full text Add to dashboard Cite

Recombinant antibodies are highly specific detection probes in research, diagnostics, and have emerged over the last two decades as the fastest growing class of therapeutic proteins. Antibody generation has been dramatically accelerated by in vitro selection systems, particularly phage display. An increasing variety of recombinant production systems have been developed, ranging from Gram-negative and positive bacteria, yeasts and filamentous fungi, insect cell lines, mammalian cells to transgenic plants and animals. Currently, almost all therapeutic antibodies are still produced in mammalian cell lines in order to reduce the risk of immunogenicity due to altered, non-human glycosylation patterns. However, recent developments of glycosylation-engineered yeast, insect cell lines, and transgenic plants are promising to obtain antibodies with “human-like” post-translational modifications. Furthermore, smaller antibody fragments including bispecific antibodies without any glycosylation are successfully produced in bacteria and have advanced to clinical testing. The first therapeutic antibody products from a non-mammalian source can be expected in coming next years. In this review, we focus on current antibody production systems including their usability for different applications.

show abstract

Section: Antibody Production In Prokaryotic Hostsmentioning

confidence: 99%

Expression of Recombinant Antibodies

Frenzel¹,

Hust²,

Schirrmann³

2013

Front. Immunol.

279

220

View full text Add to dashboard Cite

show abstract

“…This strategy also allowed yielding for the first time a functional antibody Fab fragment in E. coli [16]. At present, the translocation of the synthe sized chains of antibody fragments is provided by several leader peptides: ompA, PhoA, PelB (for periplasmic expression) [17][18][19] and stII (for secretory expression) [20,21].…”

Section: Resultsmentioning

confidence: 99%

Neutralizing monoclonal and chimeric antibodies to human interferon-γ

et al. 2015

View full text Add to dashboard Cite

Autoiminune disorders are chronic diseases characterized by abnormal immune response directed against self-antigens that leads to tissue damage and violation of its normal functioning. Such diseases often result in disability or even death of patients. Nowadays a number of monoclonal antibodies to pro-inflammatory cytokines and their receptors are successfully used for the targeted treatment of autoimmune diseases. One of the perspective targets in autoimmune disease therapy is interferon gamma, a key cytokine in Th1 cells differentiation, activation of macrophages, and inflammation. In the present work, 5 monoclonal antibodies to human IFN-γ were obtained. For the development of potential therapeutic agent, we have performed neutralizing activity and affinity analysis of the antibodies. Based on the data obtained, the monoclonal antibody F1 was selected. This antibody has a dissociation constant 1.7 x 10(-9) M and IC90 = 8.9 ± 2.0 nM measured upon antibody inhibition of the IFN-γ-induced HLA-DR expression on the surface of U937 cells. We have constructed a bicistronic vector for the production of recombinant chimeric Fab fragment F1 chim in E. coli cells. The recombinant chimeric Fab fragment Fl chim neutralizes IFN-γ activity in vitro and has a dissociation constant 1.8 x 10(-9) M.

show abstract

“…Este conhecimento sobre os vetores virais e a respectiva resposta imune humoral decorrente da terapia gênica pode ser aplicado para uma possível forma de detecção para o doping genético. Diante disso, exames imunológicos que avaliam os anticorpos destes vetores poderiam ser utilizados (MI et al, 2005). Entretanto, o atleta pode estar naturalmente infectado com um determinado vírus como o AAV, que é largamente disseminado nos tecidos humanos (GAO et al, 2004).…”

Section: Resposta Imune Humoral De Vetores De Terapia Gênicaunclassified

Doping genético e possíveis metodologias de detecção

Bairros

Prevedello²,

Moraes³

2011

Rev. Bras. Ciênc. Esporte

View full text Add to dashboard Cite

O doping genético caracteriza-se pelo uso não terapêutico de células, genes e elementos gênicos, ou a modulação da expressão gênica com objetivo de aumentar o desempenho esportivo. Isto somente pode ser realizado através de manipulação gênica. Esta prática dopante caracteriza-se como virtualmente "indetectável", o que representa novos desafios analíticos para sua detecção. Esta revisão apresenta o doping genético e possíveis métodos de detecção para evitar futuras fraudes desportivas.

show abstract

Isolation and characterization of an anti-recombinant erythropoietin single-chain antibody fragment using a phage display antibody library

Cited by 7 publications

References 19 publications

Expression of Recombinant Antibodies

Expression of Recombinant Antibodies

Neutralizing monoclonal and chimeric antibodies to human interferon-γ

Doping genético e possíveis metodologias de detecção

Contact Info

Product

Resources

About